<DOC>
	<DOC>NCT02504216</DOC>
	<brief_summary>The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.</brief_summary>
	<brief_title>Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Age â‰¥50 Documented moderate to severe symptomatic lower extremity atherosclerotic peripheral artery disease Technically successful peripheral revascularization distal to the external iliac artery for symptomatic PAD (Peripheral artery disease) within the last 10 days prior to randomization Patients undergoing revascularization for asymptomatic peripheral artery disease, or mild claudication without functional limitation Patients undergoing revascularization of the index leg to treat an asymptomatic or minimally symptomatic restenosis of a bypass graft or target lesion restenosis Prior revascularization on the index leg within 10 days of the qualifying revascularization Planned dual antiplatelet therapy use for the qualifying revascularization procedure of clopidogrel in addition to Aspirin for &gt;30 days after the qualifying revascularization procedure (or &gt; 60 days for a labeled indication [e.g. drug coated stent or ballon]) Planned dual antiplatelet therapy use for any other indication(s) with any P2Y12 antagonists in addition to Aspirin after the qualifying revascularization procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Xarelto</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Acetylic salicylic acid</keyword>
	<keyword>Anticoagulant</keyword>
	<keyword>Peripheral artery disease</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>Revascularization</keyword>
	<keyword>Acute limb ischemia</keyword>
	<keyword>Amputation</keyword>
	<keyword>Cardiovascular events</keyword>
</DOC>